From the Centers for Disease Control and Prevention. Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin.
D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000904:Antibiotics, Antitubercular / Q000494:pharmacology / Q000627:therapeutic use*; D000075202:Contraindications; D004347:Drug Interactions; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D017410:Practice Guidelines as Topic; D012293:Rifampin / Q000494:pharmacology / Q000627:therapeutic use*; D014376:Tuberculosis / Q000150:complications* / Q000188:drug therapy*
D019380:Anti-HIV Agents; D000904:Antibiotics, Antitubercular; D017320:HIV Protease Inhibitors; D012293:Rifampin